Author: Schlesinger, Naomi; Firestein, Bonnie L.; Brunetti, Luigi
Title: Colchicine in COVID-19: an Old Drug, New Use Cord-id: 91uwu2vo Document date: 2020_7_18
ID: 91uwu2vo
Snippet: PURPOSE OF REVIEW: Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) infection, is a pandemic causing havoc globally. Currently, there are no Food and Drug Administration (FDA)-approved drugs to treat COVID-19. In the absence of effective treatment, off-label drug use, in lieu of evidence from published randomized, double-blind, placebo-controlled clinical trials, is common in COVID-19. Although it is vital to treat affected patients with
Document: PURPOSE OF REVIEW: Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) infection, is a pandemic causing havoc globally. Currently, there are no Food and Drug Administration (FDA)-approved drugs to treat COVID-19. In the absence of effective treatment, off-label drug use, in lieu of evidence from published randomized, double-blind, placebo-controlled clinical trials, is common in COVID-19. Although it is vital to treat affected patients with antiviral drugs, there is a knowledge gap regarding the use of anti-inflammatory drugs in these patients. RECENT FINDINGS: Colchicine trials to combat inflammation in COVID-19 patients have not received much attention. We await the results of ongoing colchicine randomized controlled trials in COVID-19, evaluating colchicine’s efficacy in treating COVID-19. SUMMARY: This review gives a spotlight on colchicine’s anti-inflammatory and antiviral properties and why colchicine may help fight COVID-19. This review summarizes colchicine’s mechanism of action via the tubulin-colchicine complex. Furthermore, it discussed how colchicine interferes with several inflammatory pathways, including inhibition of neutrophil chemotaxis, adhesion, and mobilization; disruption of superoxide production, inflammasome inhibition, and tumor necrosis factor reduction; and its possible antiviral properties. In addition, colchicine dosing and pharmacokinetics, as well as drug interactions and how they relate to ongoing, colchicine in COVID-19 clinical trials, are examined.
Search related documents:
Co phrase search for related documents- abdominal pain and acute respiratory sars syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- accessory protein and action mechanism: 1
- accessory protein and activation formation: 1
- accessory protein and acute respiratory sars syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- accessory protein and adenosine triphosphate: 1, 2
- accessory protein sars cov and acute respiratory sars syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18
- action mechanism and acute respiratory sars syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- action mechanism and adenosine triphosphate: 1, 2
- action mechanism and adhesion molecule: 1, 2, 3
- action mechanism and adhesion molecule expression: 1
- action onset and acute respiratory sars syndrome: 1
- activation assembly and acute respiratory sars syndrome: 1, 2, 3
- activation assembly and adenosine triphosphate: 1
- activation formation and acute respiratory sars syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
- activation formation and adenosine triphosphate: 1
- activation formation inflammasome and acute respiratory sars syndrome: 1
- activation formation inflammasome and adenosine triphosphate: 1
- active production and acute respiratory sars syndrome: 1
- active production and adenosine triphosphate: 1, 2
Co phrase search for related documents, hyperlinks ordered by date